Pediatric Anesthesia and Critical Care Journal (PACCJ) (Aug 2023)

Hematuria during prolonged administration of ketamine to treat bronchospasm and respiratory failure in a toddler.

  • M. Zlotolow,
  • M. Bozych,
  • J. D. Tobias

DOI
https://doi.org/10.14587/paccj.2023.15
Journal volume & issue
Vol. 11, no. 2
pp. 109 – 115

Abstract

Read online

Given its ability to provide both sedation and analgesia, ketamine remains a popular agent for various clinical sce- narios in infants and children including the induction of anesthesia, procedural sedation, ICU sedation, and the treatment of pain. Additionally, it has been used as a ther- apeutic agent in the treatment of status asthmaticus and status epilepticus. In general, it has a wide therapeutic in- dex with a limited adverse effect profile that most com- monly includes tachycardia, hypertension, sialorrhea, and emergence delirium. We present a 2-year-old child with a complex past medical history, including extreme prematurity and chronic lung disease including bron- chopulmonary dysplasia (BPD), who developed hematuria following the prolonged administration of ket- amine infusion in the ICU setting. The adverse effect pro- file of ketamine is reviewed, previous reports of hematu- ria following its use presented, and potential mechanisms of this adverse effect discussed.

Keywords